We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00481143
Recruitment Status : Completed
First Posted : June 1, 2007
Last Update Posted : May 31, 2017
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:

The purpose of this study is to investigate the effects of iron chelation using deferasirox in low and INT-1 risk (referring to the international prognostic scoring system, IPSS) MDS patients who show signs of iron overload due to repeated blood transfusions.

This trial is not recruiting patients in the United States.

Condition or disease Intervention/treatment Phase
Myelodysplastic Syndromes Transfusion Dependent Iron Overload Drug: ICL670/Deferasirox Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 63 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 in Patients Diagnosed With Low and INT-1 Risk Myelodysplastic Syndrome (MDS) and Transfusion-dependent Iron Overload
Study Start Date : May 2007
Actual Primary Completion Date : November 2010

Arm Intervention/treatment
Experimental: deferasirox Drug: ICL670/Deferasirox
Other Name: ICL670

Primary Outcome Measures :
  1. To assess iron chelation by comparing serum ferritin values at baseline vs. 52 weeks of treatment with deferasirox [ Time Frame: 52 weeks ]

Secondary Outcome Measures :
  1. Safety and tolerability of deferasirox assessed by monitoring and recording all adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: 52 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • MDS patients presenting with low or intermediate-1 IPSS risk and transfusional iron overload
  • Patients of either gender and age ≥ 18 years
  • History of at least 20 units of red blood cell transfusions or 100mL/kg of prepacked red blood cells (PRBCs)
  • Patients can be either naïve to iron chelation or have had prior treatment with deferoxamine (DFO) or deferiprone (L1)
  • Females of childbearing potential must use double-barrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation or be postmenopausal defined by amenorrhea for at least 12 months.

Exclusion Criteria:

  • Non-transfusion related iron overload
  • Treatment with deferasirox (ICL670) before study start
  • Patients with a concomitant malignant disease
  • Patients with out of range lab values
  • History of nephrotic syndrome
  • Patients with a previous history of clinically relevant ocular toxicity related to iron chelation
  • Systemic diseases (cardiovascular, renal, hepatic, etc.) which would prevent the patient from undergoing study treatment
  • Patients treated with systemic investigational drugs within the past 4 weeks or topical investigational drug within the past 7 days
  • Any other surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug.
  • Patients with active uncontrolled infectious disease
  • Pregnancy or breast feeding

Other protocol-defined inclusion/exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00481143

Layout table for location information
Novartis Investigative Site
Berlin, Germany, 12200
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmeceuticals
Publications of Results:
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00481143    
Other Study ID Numbers: CICL670ADE03
First Posted: June 1, 2007    Key Record Dates
Last Update Posted: May 31, 2017
Last Verified: November 2016
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Myelodysplastic Syndrome
iron overload
serum ferritin
transfusional hemosiderosis
Refractory Anemia
Refractory Anemia with Ringed Sideroblasts
blood transfusions
Mydelodysplastic Syndrome(s)
Additional relevant MeSH terms:
Layout table for MeSH terms
Myelodysplastic Syndromes
Iron Overload
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Iron Metabolism Disorders
Metabolic Diseases
Iron Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action